The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effect of Pluronic P85 on ATPase Activity of Drug Efflux Transporters
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“Beside the NBDs the efflux proteins contain two membrane-embedded domains, which span the cellular membrane and form high affinity drugbinding sites (4,5,38,39).”
BackgroundDanson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382 · cited 1×
“One Pluronic-based formulation of doxorubicin is currently evaluated in clinical trials for treatment of MDR tumors (11).”
BackgroundSelf-citationKozlov, M. Y., Melik-Nubarov, N. S., Batrakova, E. V., & Kabanov, A. V. (2000) · Macromolecules · doi:10.1021/ma991634x · Cited by 322
Self-citation
Cited by
Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.013 · Cited by 1,278
“It was suggested that inhibition of drug efflux transporters occurs due to conformational changes in the efflux proteins and/or sterically hindrance of protein-drug interaction in the appropriate binding sites induced by the immersed copolymer chains in the plasma membranes [60].”
BackgroundSelf-citationModern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,006
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Oral delivery of anticancer drugs: Challenges and opportunities
Thanki, K., Gangwal, R. P., Sangamwar, A. T., & Jain, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.020 · Cited by 499
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
“Concomitant administration of P-gp inhibitors LY335979 and the dual P-gp/Bcrp inhibitor GF120918 along with cediranib resulted in significantly increased brain concentrations in mice [60].”
BackgroundInfluentialRecent Advances in the Application of Vitamin E TPGS for Drug Delivery
Yang, C., Wu, T., Qi, Y., & Zhang, Z. (2018) · Theranostics · doi:10.7150/thno.22711 · Cited by 402
Recent progress in biomedical applications of pluronic (PF127): Pharmaceutical perspectives
Akash, M. S. H., & Rehman, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.032 · Cited by 394
Polymeric micelles for oral drug delivery
Gaucher, G., Satturwar, P., Jones, M.-C., Furtos, A., & Leroux, J.-C. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.06.007 · Cited by 389
On the biodegradability of polyethylene glycol, polypeptoids and poly(2-oxazoline)s
Ulbricht, J., Jordan, R., & Luxenhofer, R. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.029 · Cited by 348
Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress
Dong, X., & Mumper, R. J. (2010) · Nanomedicine · doi:10.2217/nnm.10.35 · Cited by 317
Cho, H.-J., Yoon, H. Y., Koo, H., Ko, S.-H., Shim, J.-S., Lee, J.-H., Kim, K., Chan Kwon, I., & Kim, D.-D. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.028 · Cited by 304
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Self-citationCollnot, E.-M., Baldes, C., Wempe, M. F., Kappl, R., Hüttermann, J., Hyatt, J. A., Edgar, K. J., Schaefer, U. F., & Lehr, C.-M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060121r · Cited by 280
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders
Kabanov, A. V., & Gendelman, H. E. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.014 · Cited by 277
Self-citationPluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Self-citationPoloxamer 407/TPGS mixed micelles as promising carriers for cyclosporine ocular delivery
Grimaudo, M. A., Pescina, S., Padula, C., Santi, P., Concheiro, A., Alvarez-Lorenzo, C., & Nicoli, S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00939 · Cited by 138
How do polymeric micelles cross epithelial barriers?
Pepić, I., Lovrić, J., & Filipović-Grčić, J. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.04.012 · Cited by 102
Boosting drug bioavailability in men but not women through the action of an excipient
Mai, Y., Ashiru-Oredope, D. A. I., Yao, Z., Dou, L., Madla, C. M., Taherali, F., Murdan, S., & Basit, A. W. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119678 · Cited by 28
Metadata
- Authors
- Batrakova, E. V., Li, S., Li, Y., Alakhov, V. Y., & Kabanov, A. V.
- Venue
- Pharmaceutical Research
- Published
- 2004-12
- Volume
- 21
- Issue
- 12
- Pages
- 2226-2233
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2032879526
- Cited by
- 158
- References
- 3
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.